Journals / Fırat Tıp Dergisi / 2019 / Cilt: 24 - Sayı: 4

Diagnostic Use of Immunohistochemical Markers in Benign and Malignant Thyroid Lesions

Benign ve Malign Tiroid Lezyonlarının Ayırımında İmmünhistokimyanın Kullanımı

Pages
231–236
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was concluded that three markers except CITED1 were particularly useful in the differentiation of benign and malignant.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is evaluate benign and malignant thyroid lesions and evaluate the contribution of various diagnostic immunohistochemical markers such as CK19, HBME1, CITED1 and Galectin3.
📊
Key Findings & Data:Material and Method: This retrospective study includes 121 cases which were diagnosed as FA, FC, PC and AN/HN.
💡
Conclusion & Impact:It was concluded that three markers except CITED1 were particularly useful in the differentiation of benign and malignant.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is evaluate benign and malignant thyroid lesions and evaluate the contribution of various diagnostic immunohistochemical markers such as CK19, HBME1, CITED1 and Galectin3. Material and Method: This retrospective study includes 121 cases which were diagnosed as FA, FC, PC and AN/HN. Cases were reviewed again and immunohistochemical markers were studied by the suitable paraffin blocks. By the staining of the lesion, 10% and upper levels of expression were accepted as positive. In addition, the intensity of the expression was interpreted in three degrees (mild-moderate-strong). The results were evaluated statistically. Pearson Chi-square test was used to compare qualitative data. Significance level was taken as p <0,05. Results: The positive and negative expression rates demonstrated by immunohistochemical markers and the comparative results are shown at the tables. Conclusion: In the differentiation of benign and malignant lesions of the thyroid, these three immunohistochemical markers other than CITED1 should be used. It was concluded that three markers except CITED1 were particularly useful in the differentiation of benign and malignant. Other results are given in the conclusion of the article.

Özet

gibi değişik potansiyel tanısal immünhistokimyasal belirleyicilerin katkısını araştırmak. Gereç ve Yöntem: Bu retrospektif çalışmaya FA, FC, PC ve AN/HN tanısı almış toplam 121 vaka dahil edilmiştir. Vakalar tekrar gözden geçirildikten sonra uygun bloklara immünhistokimyasal işaretleyiciler çalışılmıştır. Lezyonun %10 ve üstünün boyanması pozitif olarak kabul edilmiştir. Ayrıca lezyonların boyanma yoğunluğu üç dereceye ayrılarak (hafif-orta-kuvvetli) yorumlanmıştır. Sonuçlar istatistiksel olarak değerlendirilmiştir. Niteliksel verilerin karşılaştırılmasında Pearson Ki-kare testi kullanılmıştır. Anlamlılık düzeyi p <0,05 olarak alınmıştır. Bulgular: Tüm vakaların İHK işaretleyiciler ile pozitif ve negatif boyanma oranları, lezyonlara göre tekli, ikili ve üçlü olarak karşılaştırmalı sonuçları tablolar ile gösterilmiştir. Sonuç: Tiroidin benign ve malign lezyonlarının ayrımında CITED1 dışındaki bu üç immünhistokimyasal işaretleyici panel halinde kullan ılmalıdır. CITED1 dışındaki diğer üç işaretleyicinin özellikle benign-malign ayırımında yararlı olduğu sonucuna varılmıştır. Diğer önemli sonuçlar makale içinde verilmiştir.

🔖

Cite This Article

SAYGIN, İ., REİS, A., ÖZORAN, Y., ÇOBANOĞLU, Ü. (2019). Diagnostic Use of Immunohistochemical Markers in Benign and Malignant Thyroid Lesions. Fırat Tıp Dergisi, Cilt: 24 - Sayı: 4, 231–236. https://ajindex.com/articles/161010

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. De Lellis R. Tumours of the thyroid and parathyroid. Tumors, Pathology and Genetics of Endocrine Organs, WHO Blue Books. Lyon İARC Pres 2004; 50-66
  2. Rosai J. Thyroid gland. In: Rosai J eds. Rosai and Ackerman’s Surgical Pathology. 10th ed. Vol I, Mosby 2011; 496-524 3. Manju L Prasad, Natalia S Pellegata, Ying Huang, et al. Galectin3, fibronectin1, CITED1, HBME1 and cytokeratin19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Modern Pathology 2005;18: 48-57 4. Beesley MF, McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 2002; 41: 236-43
  3. Saxen E, Franssila K, Bjarnason O, et al. Observer variation in histologic classification of thyroid cancer. Acta Pathol Microbiol Scand 1978; 86: 483-6
  4. Scognamiglio T, Hyjek E, Kao J, et al. Diagnostic usefulness of HBME1, Galectin-3, CK19, and CITED1 and Evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 2006; 126: 700-8 7. Manju L. Prasad, Natalia S. Pellegata, Richard T. Kloos, et al. CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid 2004; 14: 169-75
  5. Park YJ, Kwak SH, Kim DC, et al. Diagnostic value of Galectin-3, HBME1, Cytokeratin 19, High Molecular Weight Cytokeratin, Cyclin D1 and p27 in the differential diagnosis of thyroid nodules. J Korean Med Sci 2007; 22: 621-8
  6. Aratake Y, Umeki K, Kiyoyama K. Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol 2002; 26: 366-72
  7. Inohara H, Honjo Y, Yoshii T, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999; 85: 2475-84
  8. Oestreicher-Kedem Y, Halpern M, Roizman P, et al. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck 2004; 26: 960-6
  9. Coli A, Bigotti G, Zucchetti F, et al. Galectin-3, a marker of well differentiated thyroid carcinoma, is expressed in thyroid nodules. Histopathology 2002; 40: 80-7
  10. Suh YJ, Moon HJ, Choe JY, et al. the cancer genome atlas validation of ancillary tests for classifying papillary thyroid carcinoma. Int J Thyroidol 2017; 10: 24-35
  11. Dockhorn-Dworniczak B, Frank WW, Schroder S, et al. Patterns of cytoskeletal proteins in